Objectives In this study covering all of Turkey, we aimed to define cutaneous and systemic adverse reactions in our patient population after COVID‐19 vaccination with the Sinovac/CoronaVac (inactivated SARS‐CoV‐2) and Pfizer/BioNTech (BNT162b2) vaccines. Methods This prospective, cross‐sectional study included individuals presenting to the dermatology or emergency outpatient clinics of a total of 19 centers after having been vaccinated with the COVID‐19 vaccines. Systemic, local injection site, and non‐local cutaneous reactions after vaccination were identified, and their rates were determined. Results Of the 2290 individuals vaccinated between April 15 and July 15, 2021, 2097 (91.6%) received the CoronaVac vaccine and 183 (8%) BioNTech. Systemic reactions were observed at a rate of 31.0% after the first CoronaVac dose, 31.1% after the second CoronaVac dose, 46.4% after the first BioNTech dose, and 46.2% after the second BioNTech dose. Local injection site reactions were detected at a rate of 35.6% after the first CoronaVac dose, 35.7% after the second CoronaVac dose, 86.9% after the first BioNTech dose, and 94.1% after the second BioNTech dose. A total of 133 non‐local cutaneous reactions were identified after the CoronaVac vaccine (2.9% after the first dose and 3.5% after the second dose), with the most common being urticaria/angioedema, pityriasis rosea, herpes zoster, and maculopapular rash. After BioNTech, 39 non‐local cutaneous reactions were observed to have developed (24.8% after the first dose and 5% after the second dose), and the most common were herpes zoster, delayed large local reaction, pityriasis rosea, and urticaria/angioedema in order of frequency. Existing autoimmune diseases were triggered in 2.1% of the patients vaccinated with CoronaVac and 8.2% of those vaccinated with BioNTech. Conclusions There are no comprehensive data on cutaneous adverse reactions specific to the CoronaVac vaccine. We determined the frequency of adverse reactions from the dermatologist's point of view after CoronaVac and BioNTech vaccination and identified a wide spectrum of non‐local cutaneous reactions. Our data show that CoronaVac is associated with less harmful reactions while BioNTech may result in more serious reactions, such as herpes zoster, anaphylaxis, and triggering of autoimmunity. However, most of these reactions were self‐limiting or required little therapeutic intervention.

Purpose This study aimed to investigate the relationship between skin parameters and CAD. Materials and Methods The study included 50 patients diagnosed with coronary artery disease as the patient group and 45 volunteers without any known coronary artery disease as the control group. The participants' skin TEWL, pH, temperature, electrical capacitance, sebum, and elasticity values were measured using noninvasive methods at the forehead, back, and forearm. Findings Skin temperature was significantly higher in the back and forehead regions in the patient group. No difference was found between the sebum values of the patient and control groups at the back and forehead. A significantly higher result was obtained for the forearm area. The pH was significantly lower in the patients' forearm, although the obtained values were within the normal range. The TEWL was significantly higher in patients in all three regions. In terms of flexibility, R2 was significantly higher in the back and forehead regions of the patient group, and the R6 was significantly higher in the patient group in all three regions. In addition, there was no correlation between skin parameter and SYNTAX score increase measurements. Conclusion It can be suggested that skin sebum and TEWL measurements can be accepted as cheap and noninvasive methods of predicting CAD.

No abstract

No abstract

Amaç: Bu çalışmada vitiligolu hastaların serumlarında proinflamatuvar karakterde olan interferon-gamma (IFN-γ) ve antiinflamatuvar karakterde olan interlökin (IL)-10 seviyeleri ve bu sitokinlerin birbiriyle olan oranı; bunların hastalığın yaygınlığı ve aktivitesi ile ilişkili olup olmadığını araştırmak amaçlanmıştır. Gereç ve Yöntem: Çalışmaya klinik olarak vitiligo tanısı konulan 42 hasta ve 42 kontrol alındı. Serum IFN-γ, IL-10, antinükleer antikor (ANA), C-reaktif protein (CRP) seviyeleri ölçüldü; vitiligo alan şiddet indeksi (VASI) ve vitiligo hastalık aktivite skoru (VIDA) değerleri hesaplandı ve uygun istatiksel analizler yapıldı. Bulgular: Hasta ve kontrol grubu arasında IFN-γ, IL-10, ANA, CRP seviyeleri ve IFN-γ / IL-10 oranı açısından anlamlı fark bulunmadı. VASI > 200 (yaygın tutulumlu hastalar) olan hastalarla, kontrol grubu karşılaştırıldığında IL-10 değerleri arasında anlamlı farklılık saptandı (p= 0,02). VIDA > 2 (son 6 ayda yeni lezyon çıkışı olan, aktif hastalar) hastalarda IL-10 seviyeleri arasında yapılan korelasyon analizinde serum IL-10 değerinin pozitif yönde etkilendiği gözlendi (p= 0,028; r= 0,656). Hastalık süresinin IL-10 üzerine etkisi olup olmadığı değerlendirildiğinde korelasyon saptandı (p= 0,034). Bu korelasyonun negatif yönde orta derecede ilişkili olduğu saptandı (r = -0,502). IFN-γ / IL-10 oranı VASI > 200 olan hastalar ile VIDA > 2 olan hastalarda kontrole kıyasla anlamlı derecede yüksek bulundu (p= 0,04; p= 0,018). Sonuç: Çalışmamızda en çok dikkat çeken sonuç, IL-10 seviyesinin hastalığın aktif döneminde ve yaygın tutulumu olan hastalarda anlamlı derecede yüksek bulunmasıydı. Bu çalışma, yüksek sitokin seviyelerinin, melanosit hasarının daha geniş alanlarda gözlenmesinin nedeni olduğunu ve vitiligo patogenezinde otoimmün sürecin önemli derecede katkısı olduğunu göstermiştir.